↓
 

ParagraphFour.com

Pharmaceutical Patent Database

ParagraphFour.com
  • Home
  • About
  • Paragraph IV Explained
  • FAQ & Terms
  • The PIV Blog
  • PIV Data
    • Get Access
Home→parryashford

parryashford

Profile picture of parryashford

@parryashford

Active 3 days ago
  • Home
  • Activity
  • Profile
  • Forums

Recent Posts

  • 2020 Annual Review – Market Correction
  • IPRs Falling
  • No Longer Competing PIV Cases
  • Competing Paragraph IV Cases
  • 2020 PIV First-Filings, thus far

Recent Comments

    Archives

    • January 2021
    • October 2020
    • September 2020
    • July 2020
    • May 2020
    • April 2020
    • February 2020
    • January 2020
    • December 2019
    • November 2019
    • October 2019
    • August 2019
    • July 2019

    Categories

    • The PIV Blog

    Meta

    • Log in
    • Entries feed
    • Comments feed
    • WordPress.org

    Latest updates

    The Paragraph Four Report®
    Paragraph IV Activity for February 2021

    New Certifications as reported by FDA on February 8 and 23, 2021

    1. Katerzia®(amlodipine) Oral Suspension 1 mg/mL on 12/29/2020
    2. Balcoltra®(levonorgestrel and ethinyl estradiol) 0.1 mg/0.02 mg 7/14/2020
    3. Osphena®(ospemifene) Tablets 60 mg on 12/29/2020
    4. Car…Read more

    Profile picture of parryashford 1 week, 2 days ago

    The Paragraph Four Report®
    Paragraph IV Activity for January 2021

    New Certifications as reported by FDA on January 26, 2021

    1. Tirosint®(levothyroxine) Capsules 112 mcg on 12/18/2020
    2. Ibrance®(palbociclib) Tablets 75 mg, 100mg, and 125mg on 11/24/2020
    3. Xeljanz XR®(tofacitinib) Extended-release Tablets 22 mg on 12/28/2020
    4. Ore…Read more

    Profile picture of parryashford 1 month, 1 week ago

    Makena®(hydroxyprogesterone) Injection
    Annual Sales
    Company COVIS PHARMA (AMAG)
    Date of First Filing September 28, 2020

    Paragraph IV Applicant: Aurobindo
    Case Name: COVIS PHARMA GMBH et al v. EUGIA PHARMA SPECIALTIES LTD et al
    Court/Case #: Delaware District Court (dedc) 1:2021cv00003
    Date Filed: 1/4/21
    Judge: Connelly
    Product…Read more

    Profile picture of parryashford 1 month, 4 weeks ago
    Log In

    Search

    Latest Updates

    The Paragraph Four Report®
    Paragraph IV Activity for February 2021

    New Certifications as reported by FDA on February 8 and 23, 2021

    1. Katerzia®(amlodipine) Oral Suspension 1 mg/mL on 12/29/2020
    2. Balcoltra®(levonorgestrel and ethinyl estradiol) 0.1 mg/0.02 mg 7/14/2020
    3. Osphena®(ospemifene) Tablets 60 mg on 12/29/2020
    4. Car…Read more

    Profile picture of parryashford 1 week, 2 days ago

    The Paragraph Four Report®
    Paragraph IV Activity for January 2021

    New Certifications as reported by FDA on January 26, 2021

    1. Tirosint®(levothyroxine) Capsules 112 mcg on 12/18/2020
    2. Ibrance®(palbociclib) Tablets 75 mg, 100mg, and 125mg on 11/24/2020
    3. Xeljanz XR®(tofacitinib) Extended-release Tablets 22 mg on 12/28/2020
    4. Ore…Read more

    Profile picture of parryashford 1 month, 1 week ago

    Makena®(hydroxyprogesterone) Injection
    Annual Sales
    Company COVIS PHARMA (AMAG)
    Date of First Filing September 28, 2020

    Paragraph IV Applicant: Aurobindo
    Case Name: COVIS PHARMA GMBH et al v. EUGIA PHARMA SPECIALTIES LTD et al
    Court/Case #: Delaware District Court (dedc) 1:2021cv00003
    Date Filed: 1/4/21
    Judge: Connelly
    Product…Read more

    Profile picture of parryashford 1 month, 4 weeks ago

    Login

    Log In

    Search Forums

    Recent Topics

    • February 2021
    • 206. January 2021
    • Makena®(hydroxyprogesterone) Injection

    Login

    Log In

    Latest updates

    The Paragraph Four Report®
    Paragraph IV Activity for February 2021

    New Certifications as reported by FDA on February 8 and 23, 2021

    1. Katerzia®(amlodipine) Oral Suspension 1 mg/mL on 12/29/2020
    2. Balcoltra®(levonorgestrel and ethinyl estradiol) 0.1 mg/0.02 mg 7/14/2020
    3. Osphena®(ospemifene) Tablets 60 mg on 12/29/2020
    4. Car…Read more

    Profile picture of parryashford 1 week, 2 days ago

    The Paragraph Four Report®
    Paragraph IV Activity for January 2021

    New Certifications as reported by FDA on January 26, 2021

    1. Tirosint®(levothyroxine) Capsules 112 mcg on 12/18/2020
    2. Ibrance®(palbociclib) Tablets 75 mg, 100mg, and 125mg on 11/24/2020
    3. Xeljanz XR®(tofacitinib) Extended-release Tablets 22 mg on 12/28/2020
    4. Ore…Read more

    Profile picture of parryashford 1 month, 1 week ago

    Makena®(hydroxyprogesterone) Injection
    Annual Sales
    Company COVIS PHARMA (AMAG)
    Date of First Filing September 28, 2020

    Paragraph IV Applicant: Aurobindo
    Case Name: COVIS PHARMA GMBH et al v. EUGIA PHARMA SPECIALTIES LTD et al
    Court/Case #: Delaware District Court (dedc) 1:2021cv00003
    Date Filed: 1/4/21
    Judge: Connelly
    Product…Read more

    Profile picture of parryashford 1 month, 4 weeks ago

    Login

    Log In

    Latest updates

    The Paragraph Four Report®
    Paragraph IV Activity for February 2021

    New Certifications as reported by FDA on February 8 and 23, 2021

    1. Katerzia®(amlodipine) Oral Suspension 1 mg/mL on 12/29/2020
    2. Balcoltra®(levonorgestrel and ethinyl estradiol) 0.1 mg/0.02 mg 7/14/2020
    3. Osphena®(ospemifene) Tablets 60 mg on 12/29/2020
    4. Car…Read more

    Profile picture of parryashford 1 week, 2 days ago

    The Paragraph Four Report®
    Paragraph IV Activity for January 2021

    New Certifications as reported by FDA on January 26, 2021

    1. Tirosint®(levothyroxine) Capsules 112 mcg on 12/18/2020
    2. Ibrance®(palbociclib) Tablets 75 mg, 100mg, and 125mg on 11/24/2020
    3. Xeljanz XR®(tofacitinib) Extended-release Tablets 22 mg on 12/28/2020
    4. Ore…Read more

    Profile picture of parryashford 1 month, 1 week ago

    Makena®(hydroxyprogesterone) Injection
    Annual Sales
    Company COVIS PHARMA (AMAG)
    Date of First Filing September 28, 2020

    Paragraph IV Applicant: Aurobindo
    Case Name: COVIS PHARMA GMBH et al v. EUGIA PHARMA SPECIALTIES LTD et al
    Court/Case #: Delaware District Court (dedc) 1:2021cv00003
    Date Filed: 1/4/21
    Judge: Connelly
    Product…Read more

    Profile picture of parryashford 1 month, 4 weeks ago

    Login

    Log In

    Latest updates

    The Paragraph Four Report®
    Paragraph IV Activity for February 2021

    New Certifications as reported by FDA on February 8 and 23, 2021

    1. Katerzia®(amlodipine) Oral Suspension 1 mg/mL on 12/29/2020
    2. Balcoltra®(levonorgestrel and ethinyl estradiol) 0.1 mg/0.02 mg 7/14/2020
    3. Osphena®(ospemifene) Tablets 60 mg on 12/29/2020
    4. Car…Read more

    Profile picture of parryashford 1 week, 2 days ago

    The Paragraph Four Report®
    Paragraph IV Activity for January 2021

    New Certifications as reported by FDA on January 26, 2021

    1. Tirosint®(levothyroxine) Capsules 112 mcg on 12/18/2020
    2. Ibrance®(palbociclib) Tablets 75 mg, 100mg, and 125mg on 11/24/2020
    3. Xeljanz XR®(tofacitinib) Extended-release Tablets 22 mg on 12/28/2020
    4. Ore…Read more

    Profile picture of parryashford 1 month, 1 week ago

    Makena®(hydroxyprogesterone) Injection
    Annual Sales
    Company COVIS PHARMA (AMAG)
    Date of First Filing September 28, 2020

    Paragraph IV Applicant: Aurobindo
    Case Name: COVIS PHARMA GMBH et al v. EUGIA PHARMA SPECIALTIES LTD et al
    Court/Case #: Delaware District Court (dedc) 1:2021cv00003
    Date Filed: 1/4/21
    Judge: Connelly
    Product…Read more

    Profile picture of parryashford 1 month, 4 weeks ago
    The Paragraph Four Report®, ParagraphFour.com® and the PFOUR logo are registered trademarks of Parry Ashford Inc. • ©Parry Ashford Inc. 2021
    ↑